Validation and cross-cultural adaptation of the COMPASS-31 in Croatian and Serbian patients with multiple sclerosis
Aim To validate and cross-culturally adapt Croatian and Serbian versions of composite autonomic symptom score- 31 (COMPASS-31) for the detection of dysautonomia in patients with multiple sclerosis (MS). Methods A total of 179 patients, 67 with clinically isolated syndrome (CIS) and 112 with MS, comp...
Gespeichert in:
Veröffentlicht in: | Croatian medical journal 2017-10, Vol.58 (5), p.342 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Aim To validate and cross-culturally adapt Croatian and
Serbian versions of composite autonomic symptom score-
31 (COMPASS-31) for the detection of dysautonomia in patients
with multiple sclerosis (MS).
Methods A total of 179 patients, 67 with clinically isolated
syndrome (CIS) and 112 with MS, completed the COMPASS-
31 at two MS centers in Zagreb and Belgrade between April
1 and October 31, 2016. Demographic and clinical data including
age, gender, MS phenotypes, and the Expanded
Disability Status Scale (EDSS) score were collected.
Results The Cronbach’s alpha coefficient of COMPASS-31
total score was 0.844 for the Croatian MS sample and 0.779
for the Serbian MS sample. A joint analysis yielded Cronbach’s
alpha coefficients ranging from 0.394 to 0.796, with
values in four domains higher than 0.700. In Croatian and
Serbian samples and the total study sample, the Cronbach’s
alpha coefficient of COMPASS-31 was 0.785. Reproducibility
measured by intra-class correlation coefficient (ICC) was
acceptable (ICC = 0.795). With regard to the clinical validity,
significant correlation was found between EDSS and
the COMPASS-31 total score (P < 0.001). Furthermore, significant
differences between MS phenotypes were detected
for bladder and gastrointestinal domains and for the
COMPASS-31 total score (P < 0.001, P = 0.005, and P = 0.027,
respectively). Finally, significant differences between MS
phenotypes in patients with score >0, which implies the
existence of at least one of the symptoms investigated in
each domain, were detected for secretomotor and bladder
domains (P = 0.015 and P < 0.001, respectively).
Conclusion COMPASS-31 represents a valid and acceptable
self-assessment instrument for the detection of dysautonomia
in MS patients |
---|---|
ISSN: | 0353-9504 1332-8166 |
DOI: | 10.3325/cmj.2017.58.342 |